🕒 Last update: loading…21/11/2026

Stock AIM ImmunoTech Inc. AIM

AIM ImmunoTech Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -93.18%

Price change 2019 → 2020: 231.43%

Price change 2020 → 2021: -48.60%

Price change 2021 → 2022: -66.30%

Price change 2022 → 2023: 41.93%

Price change 2023 → 2024: -54.54%

Price change 2024 → 2025: -94.00%

Price change 2025 → 2026: -86.33%

Price change 2026 (year to date): -87.02%

Financial growth

Revenue CAGR (8 years): -18.45%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Negative or zero equity.

P/E (Price/Earnings)

P/E ratio: -0.02

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 82.81% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
AIM ImmunoTech Inc.––−2.8 %🔒
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–
Daré Bioscience, Inc.–0.93+9.1 %–
Spineway S.A.–0.07+9.3 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by AIM ImmunoTech Inc. over the latest fiscal years.

Revenue
88,000 USD
fiscal year 2025
Net income
-14.0 m USD
fiscal year 2025
Net margin
-15,861.4 %
fiscal year 2025
Average annual growth
-11.6 %
Revenue growth over 5 years
Average annual growth
-4.0 %
Revenue growth over 10 years
Market cap
5.7 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020163,000-14.4 m-8,834.4 %n/a
2021135,000-19.1 m-14,168.1 %-17.2 %
2022141,000-19.4 m-13,790.8 %+4.4 %
2023202,000-29.0 m-14,337.6 %+43.3 %
2024170,000-17.3 m-10,188.2 %-15.8 %
202588,000-14.0 m-15,861.4 %-48.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by AIM ImmunoTech Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-67.32
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.56 x
low debt
Fiscal year20212022202320242025
Cash and investments48.3 m34.2 m13.1 m4.0 m993,000
Total Debt149,000837,000718,0002.9 m4.9 m
Net Debt-31.9 m-26.2 m-4.7 m1.2 m4.0 m
Equity56.9 m38.5 m10.2 m-1.3 m-9.8 m
Total assets57.7 m40.5 m19.4 m8.6 m5.8 m
Operating cash flow-14.0 m-16.1 m-21.3 m-14.9 m-11.0 m
Investments (capex)41,00086,000585,00018,000378,000
Free cash-flow-14.0 m-16.4 m-21.9 m-14.9 m-11.3 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.05 x
Price / book value0.55 x
Return on Equity (ROE)-789.1 %
Return on Invested Capital (ROIC)-159.3 %
Net margin-15,526.4 %
Debt / equity0.03 x
Current ratio2.75 x
Interest coverage-9.33 x
Free cash-flow yield-43.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

AIM ImmunoTech Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
17.4
healthcare, NYSE American
Sector over 10 years
8.8
10-year median, range 4.5 to 30.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
AIM ImmunoTech Inc.5.7 mn/a-15,861.4 %
KALA BIO, Inc. KALA2.7 mn/a0.0 %
Oragenics, Inc. OGEN906,903n/a0.0 %
Pasithea Therapeutics Corp. KTTA17.4 mn/a0.0 %
Quoin Pharmaceuticals, Ltd. QNRX7.4 mn/a0.0 %
Ensysce Biosciences, Inc. ENSC8.1 mn/a-200.8 %
XTL Biopharmaceuticals Ltd. XTLB1.5 mn/a0.0 %
Alaunos Therapeutics, Inc. TCRT5.6 mn/a-83,520.0 %
Can-Fite BioPharma Ltd. CANF1.9 mn/a-2,426.7 %
Sector median (NYSE American)17.4

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

AIM ImmunoTech Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
12/11/2026-0.21-0.14n/a
07/08/2026-0.43-0.17n/a
15/05/2026-0.69-1.08n/a
27/03/2026-1.36-0.94n/a
17/11/2025-1.57-0.97n/a
14/08/2025-3.68-8.00n/a

Stock splits

DateOperation
10/02/2026split: 1,031 shares for 1,000
12/06/2025reverse split: 1 share for 100
11/06/2019reverse split: 1 share for 44
29/08/2016reverse split: 1 share for 12

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in AIM ImmunoTech Inc.

Free float
68.9 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE American
IPO: 12/07/1996
ISIN code
US00901B1052
Workforce
21
full-time employees
Chief executive
Thomas K. Equels

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about AIM ImmunoTech Inc.

What is the AIM ImmunoTech Inc. share price?

Latest recorded price: 0.144 USD on 13/11/2026, for a market cap of 5.7 m USD.

What is the revenue of AIM ImmunoTech Inc.?

88,000 USD for fiscal year 2025, with net income of -14.0 m USD (net margin -15,861.4 %).

Is AIM ImmunoTech Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US00901B1052).

How many employees does AIM ImmunoTech Inc. have?

21 full-time employees according to the latest published profile.

Who runs AIM ImmunoTech Inc.?

Thomas K. Equels is the company's chief executive.

07

Similar stocks